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Abstract
Background.—Some studies have found a higher frequency of fever with trivalent live 
attenuated influenza vaccine (LAIV) than with inactivated influenza vaccine (IIV), but 
quadrivalent LAIV has not been assessed. Understanding fever is important for safety reviews and 
for parents and providers. In addition, there have been only a limited number of studies in which 
text messaging was used for vaccine adverse-event (AE) surveillance.
Methods.—We conducted a prospective observational study in 3 community clinics in New York 
City to assess post-influenza vaccination fever in 24- to 59-month-olds during the 2013–2014 
season. Enrolled families of children who received quadrivalent LAIV (LAIV4) or IIV (trivalent 
IIV3 or quadrivalent IIV4) replied to text messages that assessed their temperature on vaccination 
night and the next 10 nights (days 0 to 10); missing data were collected via telephone and a diary. 
We compared frequencies of fever (temperature ≥ 100.4°F) according to vaccine group on days 0 
to 2 and 3 to 10 by using χ2 and multivariate log-binomial regression adjusted for age, previous 
influenza vaccination, and vaccine coadministration. We also assessed outcomes using all sources 
versus only text messages.
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Results.—Most (84.1 % [n = 540]) eligible parents enrolled. Fever frequencies on days 0 to 2 did 
not differ between LAIV4 and any IIV (3.8% vs 5.7%, respectively; adjusted relative risk [aRR] 
[95% confidence interval], 0.60 [0.25–1.46]), between LAIV4 and IIV4 (4.2% vs 7.1%, 
respectively; aRR, 0.58 [0.19–1.72]), or between IIV4 and IIV3 (7.1% vs 6.0%, respectively; aRR, 
1.02 [0.30–3.46]). The findings were similar when all data sources versus textmessage data alone 
were used. There were no significant differences on days 3 to 10.
Conclusions.—Postvaccination fever frequencies were low overall and did not differ according 
to influenza vaccine type during the 2013–2014 influenza season. The similarity of results when 
data were limited to text messages lends support to its use for surveillance of vaccine adverse 
events.
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BACKGROUND
Since 2010, influenza vaccination has been recommended for all individuals aged 6 months 
or older [1]. Several studies had suggested that live attenuated influenza vaccine (LAIV) was 
more effective than inactivated influenza vaccine (IIV) in children [2–4], which prompted 
the Advisory Committee on Immunization Practices (ACIP) to review effectiveness and 
safety data, leading to a recommendation that healthy children aged 2 to 8 years receive a 
LAIV preferentially over IIV during the 2014–2015 influenza season [5]. Although this 
preference was removed during the February 2015 ACIP meeting because of new 
effectiveness data [6], understanding the safety profile of the quadrivalent LAIV (LAIV4) 
remains important. There is also a need for additional safety data for quadrivalent 
formulations that were introduced more recently [7].
The ACIP considered fever after receipt of LAIV or IIV to be an important safety review 
component [5]. Fever after vaccination is relatively common among children [8, 9]. 
Although most febrile episodes are short lived and uncomplicated, they can be associated 
with complications such as febrile seizures, especially in young children [8, 10]. Even 
uncomplicated fever can lead to increased health care utilization [11]. Fevers can also affect 
parental perception of the vaccine [12, 13], and concerns regarding vaccine adverse effects 
play an important role in vaccine decision making [14, 15]. Data regarding fever after receipt 
of LAIV or IIV are limited [2, 16]. In a study in 6- to 59-month-olds, the frequency of fever 
was higher after trivalent LAIV (LAIV3) (5.4%) than after IIV3 (2.0%) on day 2 (d2) after 
vaccination [2]. In another study, fever was more frequent after receipt of LAIV4 (5.1%) 
than after LAIV3 (3.1%) [17]. Neither study assessed coadministration of LAIV with other 
vaccines.
The primary aim of this study was to assess, through text messaging, the frequency of fever 
in 24- to 59-month-old children who received LAIV or IIV. We hypothesized that the 
frequency of fever on the vaccination day and in the first 2 days after vaccination (d0 to d2) 
would be higher in those who received LAIV than in those who received IIV. The d0 to d2 
window was selected because of the increased fever risk observed on d2 after vaccination 
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with LAIV in a previous study [2] and the known d0 to d1 fever-risk window after IIV [18]. 
The main secondary study aims included determining (1) the clinical importance of reported 
fevers, (2) frequency of fever on d0 to d2 in children who received IIV4 versus those who 
received IIV3, and (3) fever on d3 to d10. We also assessed the validity of using text 
messaging for vaccine adverse-event (AE) surveillance. Although we had successfully used 
text messaging to assess fever frequency after simultaneous vaccination with IIV3 and 13-
valent pneumococcal conjugate vaccine (PCV13) [9], the number of studies using text 
messaging for vaccine AE surveillance is limited.
METHODS
This prospective observational study (ClinicalTrials.gov identifier NCT01764269) was 
conducted in 3 community-based clinics affiliated with NewYork-Presbyterian Hospital/
Columbia University Medical Center (CUMC) in New York City in collaboration with the 
US Centers for Disease Control and Prevention. These sites serve a primarily Latino and 
publicly insured population and share a common electronic health record system. All 
vaccination decisions were made by the patients’ health care provider and the caregiver. 
Beginning in the 2013–2014 season, all LAIV products available nationally were 
quadrivalent (LAIV4). At the study sites, both IIV3 and IIV4 were available, but IIV4 was 
available only in the dose for ≥3-year-olds. The CUMC institutional review board (IRB) 
approved the study; the Centers for Disease Control and Prevention IRB relied on the 
determination of the CUMC IRB.
Study Population and Enrollment
A pilot study was conducted between January and April 2013, and the full-season study was 
performed between September 2013 and April 2014. The influenza vaccine strain 
composition differed in the 2 seasons [19, 20]. Families were eligible to enroll if they (1) 
had a 24- to 59-month-old who was receiving his or her first influenza vaccine (LAIV or 
IIV) dose of that season at the time of enrollment, (2) had a cell phone with text-messaging 
capabilities, and (3) spoke English or Spanish. Exclusion criteria included (1) any chronic 
medical condition considered a contraindication or precaution for LAIV (with the exception 
of asthma/wheezing history) [5], (2) oral or other systemic steroid use in the previous month, 
(3) inhaled steroid use in the previous 2 weeks, (4) a temperature of ≥100.4°F at vaccination, 
(5) administration of any antipyretic within 6 hours before vaccination, (6) a stated intent to 
use prophylactic antipyretics, or (7) a parent’s inability to read text messages. Receipt of 
other vaccines was not an exclusion criterion.
After consent was obtained, each family completed an intake form including self-reported 
demographic information, reviewed the text-message procedures, and enrolled via text 
message. The families received and were trained to use a temporal artery thermometer [21]. 
Each family was also given a paper diary in a preaddressed/prestamped envelope to return 
after the 10-day observation period to receive a round-trip New York City Transit Authority 
MetroCard.
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Study Procedures
The families were asked to take their child’s temperature once per day if they thought he or 
she was afebrile or as indicated if febrile. Families were sent an interactive text message 
series on the night of vaccination and over the next 10 nights and were asked to report the 
highest temperature taken, the time that temperature was taken, name and time of any 
antipyretics given, and care sought. Study staff reviewed the messages daily and initiated 
contact with nonresponders to collect missing data and assess whether there was any trouble 
responding to messages. Using an electronic health record abstraction tool, vaccinations 
given at enrollment and at all healthcare visits (ambulatory care, pediatric emergency 
department, and hospital) to NewYork-Presbyterian Hospital/CUMC between d0 and d10 
after vaccination were recorded.
Statistical Analysis
The primary outcome assessed was fever (temperature ≥ 100.4°F [38°C]) on d0 to d2 after 
vaccination. Secondarily, we assessed moderate fever (temperature ≥ 102.2°F [39°C]) on d0 
to d2.
For both the 2012–2013 pilot and the 2013–2014 full study, we used χ2 tests to compare the 
presence of a temperature of ≥100.4°F on d0 to d2 in children who received LAIV versus 
that in children who received IIV. Children were included in this analysis if they (1) had a 
temperature of ≥100.4°F reported on d0, d1, or d2, even if a response was invalid or missing 
on other days, or (2) had valid temperature measurement (defined as a temperature of ≥95°F) 
reported on all days (d0–d2). Children with or without antipyretic use were classified as 
having a fever on the basis of the same cutoff values.
On the basis of postvaccination fever frequency in clinical studies, with a sample size of at 
least 359, we were powered to detect a 2-fold increase in fever frequency when comparing 
LAIV4 versus IIV, assuming an 80% power and 5% type I error (2-sided). A 2-fold increase 
was selected on the basis of a previous study that compared fever after LAIV versus fever 
after IIV [2]. In addition, given the overall fever estimates (5.4%–7.6%) after nonadjuvanted 
IIV in an analysis of randomized controlled trials, a less than 2-fold increase would likely 
have little clinical significance [22].
For the full 2013–2014 study, by using multivariate log-binomial regression we determined 
the association of LAIV versus IIV receipt and fever during d0 to d2 after vaccination. 
Variables that were included in the model based on a priori clinical considerations included 
age group (24–35, 36–47, and 48–59 months), history of previous influenza vaccination, 
concurrent PCV13 vaccination (based on historical association) [9], and the most commonly 
coadministered inactivated vaccines (diphtheria, tetanus, acellular pertussis, and inactivated 
poliovirus [DTaP-IPV] [Kinrix] and hepatitis A vaccine) (Supplementary Table 1). In 
addition, demographic factors (child sex and race/ethnicity [selfreported]), medical problems 
associated with high risk for influenza complications [5], and enrollment month were 
planned to be included if the P value was <.10 in univariate analyses. Pairwise correlation 
was tested via Pearson correlation coefficients, and multicollinearity was assessed on a 
linear scale.
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Five sensitivity analyses were also conducted: (1) including only children with temperature 
information reported on all days (d0 to d2); (2) including only children who received 
influenza vaccine alone without other vaccinations; (3) excluding children with reported 
antipyretic use preceding a reported temperature on d0, d1, or d2; (4) including only 
children ≥3 years old (in the indicated age range to receive either IIV type available at the 
sites); and (5) using only data collected via text message.
To verify the d0 to d2 risk window, we assessed the frequency of fever (temperature ≥ 
100.4°F) on d3 to d10. Children were included if they had a valid temperature measurement 
reported on all 8 days or reported fever on any day in that period. Analyses were adjusted for 
a priori–selected covariates that could affect fever on d3 to d10: age group, previous 
influenza vaccination, and coadministration of any of the most common live vaccines 
(measles, mumps, and rubella [MMR], varicella, or MMR–varicella [ProQuad]) 
(Supplementary Table 1).
In secondary bivariate analyses, we compared differences in the frequencies of fever after 
IIV3 versus IIV4 and after IIV4 versus LAIV4. Only children ≥3 years of age were included 
because those who were <3 years could have received only the IIV3.
RESULTS
In the 2012–2013 pilot study, we enrolled 116 children (89.9% of those eligible); 33.6% 
received IIV3. On d0 to d2, few had a temperature of ≥100.4°F (0.0% [LAIV3] vs 6.0% 
[IIV3]; P = .55, Fisher’s exact test). There were no temperatures of ≥102.2°F.
In the 2013–2014 season, 540 children (84.1% of those eligible) were enrolled; 41.9% 
received LAIV4 (Figure 1). Five enrollees were excluded from the IIV3 versus IIV4 
analyses because it was unclear which IIV formulation they received. Of the remaining 
participants, 68.3% received an IIV3. A higher proportion of 24- to 35-month-olds received 
IIV (Table 1). Daily text-message response rates varied, but on all days the majority of the 
data were collected via text messaging (Figure 2). The proportion of children for whom all 
d0 to d2 data were reported via text messaging did not differ according to vaccine type 
(81.5% [LAIV4] vs 82.9% [IIV3] vs 82.4% [IIV4]; P = .95). Only 39.1% of the participants 
returned the paper diary; the average time elapsed from d0 to diary receipt was 27 days 
(range, 8–139 days). The percentage of participants who returned the diary (41.6%–52.4% 
per response day) was higher for those who responded to text messages than for those who 
did not respond (15.2%–26.1%).
Fever on d0 to d2 After Vaccination
For the 2013–2014 season, in both unadjusted and adjusted analyses, the frequency of 
temperature ≥ 100.4°F on d0 to d2 did not differ significantly in children who received 
LAIV4 from that in those who received IIV (3.8% vs 5.7%, respectively; adjusted relative 
risk [aRR] 0.60 [95% confidence interval (CI), 0.25–1.46]) (Table 2; Supplementary Table 
2). Analyses were adjusted only for a priori–selected factors, because no additional factors 
reached a P value of <.1 (Supplementary Table 3).
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For all sensitivity analyses, the aRRs were similar: (1) for information about fever reported 
on all days (d0–d2) (aRR, 0.65 [95% CI 0.27–1.59]); (2) for those who received influenza 
vaccine alone (aRR, 0.60 [95% CI, 0.15–2.40]); (3) when we excluded those who were 
given an antipyretic (aRR, 0.64 [95% CI, 0.22–1.88]); (4) when analysis was limited to ≥3-
year-olds (aRR, 0.61 [95% CI, 0.23–1.64]); and (5) when analysis was limited to only text-
message data (aRR, 0.57 [95% CI 0.22–1.46]). The aRRs were also similar when previous 
influenza vaccination was removed from the model because of the potential for 
multicollinearity (aRR, 0.58 [95% CI, 0.24–1.42]) and when race/ethnicity (0.72 [95% CI 
0.29–1.75]) or the presence of a high-risk medical condition (0.56 [95% CI 0.23–1.36]) was 
added. We found no significant interactions between vaccine type and covariates for a 
temperature of ≥100.4°F on d0 to d2. Fever frequencies were low on all days 
(Supplementary Figure 1).
There were 4 moderate fevers (temperature ≥ 102.2°F) on d0 to d2 (LAIV4, n = 0; IIV3, n = 
2; IIV4, n = 2). Because this occurrence was uncommon, no further analyses were 
conducted. There were no significant differences in the frequencies of fever in ≥3-year-olds 
who received IIV4 vs IIV3 or in those who received an IIV4 vs LAIV4 (Table 2).
Of the 7 children who received LAIV and had fever during d0 to d2, 4 had received LAIV 
simultaneously with at least 1 inactivated vaccine (hepatitis A [n= 1] or DTaP-IPV and 
MMR–varicella [n = 3]). Of the 15 children who received IIV and had a fever on d0 to d2, 8 
had also received an inactivated vaccine (hepatitis A [n = 2], DTaP-IPV and MMR–varicella 
[n = 4], DTaP-IPV and individual MMR and varicella [n = 1], or DTaP, Haemophilus 
influenzae type b, PCV13, and hepatitis A [n= 1]).
Fever on d3 to d10 After Vaccination
Fewer families reported data for the d3 to d10 period. There were no significant between-
group differences in fever frequencies on d3 to d10 on unadjusted or adjusted analyses for 
temperatures of ≥100.4°F (LAIV4 vs IIV, 10.3% vs 9.8%, respectively; aRR, 1.07 [95% CI, 
0.55–2.08]) (Supplementary Table 4), and there were no significant interactions between 
vaccine types and covariates. There were also no significant differences for ≥3 year-olds 
who received IIV4 (6.3%) versus IIV3 (13.7%) (P = .21, Fisher’s exact test) or those who 
received IIV4 (6.3%) versus LAIV4 (12.7%) (P = .21, Fisher’s exact test). There were 10 
fevers (temperature ≥ 102.2°F) on d3 to d10 (LAIV4 [n = 6]; IIV3 [n = 3]; IIV4 [n = 1]).
On d3 to d10, of the 14 fevers in children who received LAIV4, 4 occurred in those who 
received at least 1 other live vaccine (MMR–varicella and DTaP-IPV [n = 2]; MMR and 
DTaP-IPV [n = 1]; or MMR–varicella [n = 1]). Of the 19 children with a fever on d3 to d10 
who received IIV, 6 also received a live vaccine (DTaP-IPV and MMR–varicella [n = 3]; 
DTaP-IPV, MMR, and varicella [n = 1]; MMR [n = 1]; or MMR and varicella [n = 1]).
Healthcare Utilization
There were no hospitalizations or febrile seizures noted for any participant between d0 and 
d10. Of the 22 children with a fever during d0 to d2, 2 had a medical visit. One child who 
received IIV4 alone had a d5 ambulatory care visit for an upper respiratory infection/allergy 
and a d10 pediatric emergency department (PED) visit for pharyngitis/asthma. The other 
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child who received IIV3 and a hepatitis A vaccine had a d8 PED visit for gastroenteritis. In 
the whole sample, there were 9 PED visits of any kind during d0 to d10: 2 in the LAIV4 
group (viral illness, laceration), 3 in the IIV3 group (pneumonia, vomiting, gastroenteritis), 
and 4 in the IIV4 group (blepharitis, thumb issue, diaper dermatitis, pharyngitis/asthma). 
There were 17 ambulatory care visits of any kind (LAIV4 group, n = 6; IIV3 group, n = 5; 
and IIV4 group, n = 6).
DISCUSSION
In this observational study conducted in the first season after the introduction of LAIV4 in 
the United States (2013–2014), we found no increase in the frequency of fever in 24- to 59-
month-olds who received LAIV4 versus those who received the IIV3 or IIV4. Fevers after 
any type of influenza vaccine were mild and not common, and the numbers were similar to 
estimates after nonadjuvanted IIV in an analysis of randomized controlled trials (5.4%–
7.6%) [22]. There were no hospitalizations or febrile seizures in the 10 days after 
vaccination for any vaccination type. These findings support the current recommendations 
for either type of influenza vaccine [23].
Understanding the AE profiles of different influenza vaccination types is useful for health 
care providers when providing anticipatory guidance to families. Non–medically attended 
fevers can affect parent perceptions of the vaccine, including its safety, and can lead to 
nonadherence to recommended vaccines [12, 13]. This may be particularly problematic for 
influenza vaccine, because coverage for it is lower nationally than that for other childhood 
vaccinations [24, 25], and parental concerns regarding adverse effects seem to play an 
important role in vaccine decision making [14]. Anticipatory guidance may ameliorate some 
of these concerns, but it is predicated on accurate information regarding the actual frequency 
of fever after a given vaccine.
Our study findings do not support our original hypothesis that fever would be more frequent 
after LAIV4 than after IIV, as noted previously by Belshe et al [2]. Reasons for the 
differences are not clear [2]. One potential explanation is that different viral strains might 
lead to different pyrogenicity profiles for IIV and LAIV. The strains used in the vaccine in 
the Belshe et al study were different than those used during our study. However, our finding 
of similar fever patterns over 2 seasons (pilot and full study) with different vaccine strains 
argues against this explanation.
Another possibility is that the Belshe et al study also included younger children aged 6 to 23 
months. In our study, there were no significant relationships between age and fever; 
however, all the children were at least 24 months old. A previous study that assessed IIV4 
found a slight increase in fever frequency in children <36 months old over that in 36- to 59-
month-olds [26].Continued vaccine safety surveillance over future seasons might identify 
fever patterns [27]. In addition, in our study, the point estimates for fever between d3 and 
d10 were higher than those for fever during d0 to d2; however, the CIs on adjusted analyses 
were overlapping. In addition, the observation period was longer and response rates were 
lower, and some fevers might have been caused by simultaneous measles vaccination, which 
is known to cause fever in the 5 to 12 days after vaccination [28].
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Our study results lend further support to the use of textmessage surveillance for vaccine 
adverse events in terms of feasibility and validity [9]. In this study, primary results were 
similar when analyses were limited only to data collected via text messaging and when using 
additional data collected via telephone and diary. The text-message responses were also 
greater overall and more timely. Only 39% of participants returned the paper diary, and the 
time from day of vaccination to return of the diary was prolonged. This delay would have 
made it difficult to collect samples or additional data proximal to a vaccine adverse event, if 
needed. Those with a higher text-message response rate also had a higher diary-return rate. 
Researchers in Australia also found response rates to text messages to be significantly higher 
and timelier than those to telephone interviews for AE reporting after influenza vaccination 
in pregnant women [29]. In our study, daily reporting rates dropped off in the later days of 
the 10-day period; additional studies should assess the optimal timing of text-message 
queries for prolonged data collection.
There were several limitations to this study. We were not powered to assess a less than 2-fold 
difference in fever frequencies in the LAIV4 and IIV groups on d0 to d2. However, the 
absolute differences in fever frequencies between vaccine types were very low (<3%), and in 
all the comparisons, the LAIV resulted in a lower rate. These small differences, even had we 
been powered to detect them as significant, may not be clinically relevant, given that the 
frequency of documented fevers was minimal. The study lacked power to assess differences 
in the subanalyses of fever frequency after IIV4 versus that after IIV3 or the effect of 
simultaneous vaccinations. In addition, the children were not randomly assigned to have a 
given vaccine type administered. Although potential confounders were assessed, there might 
have been residual confounding as a result of unmeasured variables. Also, because nearly all 
DTaP vaccines administered were given as a combination vaccine with IPV, we were unable 
to assess the potential effect of other DTaP-containing products. In addition, this study was 
conducted in a primarily Latino, urban population and among families of children aged 24 to 
59 months. Not all the parents responded to our text messages, and it is possible that those 
who had children who were ill were more likely to not respond; however, we did not find 
differences in outcomes when we assessed text-message–only data and when we included 
data collected via diary and telephone. Finally, vaccine strains can change from year to year, 
although similar fever patterns were seen over the pilot and full study years when the 
vaccines strains differed.
CONCLUSIONS
Administration of an LAIV was not associated with increased postvaccination fever 
frequency in children aged 24 to 59 months during the 2013–2014 influenza season. 
Postvaccination fever frequencies with all influenza vaccine types were low. For the 2015–
2016 influenza season, the ACIP recommended that LAIV4, IIV3, or IIV4 be used to 
prevent influenza in children aged ≥2 years who have no contraindications or need for 
precautions [6]. Our finding that the frequencies of fever were similar across these products 
may be informative to parents and providers when making decisions about influenza 
vaccination. Finally, the results of this study further support the use of text messaging for 
surveilling vaccine adverse events, because response rates to text messages were high 
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relative to rates of response to other sources, and results were similar when analyses were 
limited to text-message data.
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Figure 1. 
Study flow for enrollment during the 2013–2014 influenza season. aFor 5 children who 
received inactivated influenza vaccine (IIV), inadequate information regarding subtype was 
available; bAll live attenuated influenza vaccines (LAIVs) were LAIV4.
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Figure 2. 
Source of fever data for enrolled children during the 2013–2014 influenza season.
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